Gastric Ulcer Clinical Trial
Official title:
A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.
This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Completed |
NCT03291418 -
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05526339 -
HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
|
N/A | |
Completed |
NCT01435525 -
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
|
N/A | |
Terminated |
NCT00594854 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
|
Phase 3 | |
Completed |
NCT01129011 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
|
Phase 3 | |
Completed |
NCT00527787 -
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
|
Phase 3 | |
Recruiting |
NCT05517408 -
Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
|
N/A | |
Recruiting |
NCT01946633 -
Remote-controlled Capsule Endoscopy: a Feasibility Study
|
N/A | |
Completed |
NCT01964131 -
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01150162 -
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
|
Phase 3 | |
Recruiting |
NCT01037491 -
Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets
|
N/A | |
Completed |
NCT00960869 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
|
Phase 3 | |
Completed |
NCT00961350 -
A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
|
Phase 3 | |
Completed |
NCT00595517 -
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
|
Phase 3 | |
Completed |
NCT00428701 -
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
|
Phase 4 | |
Completed |
NCT01452711 -
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
|
Phase 3 | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Recruiting |
NCT03057171 -
A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA
|
||
Completed |
NCT01568398 -
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
|
Phase 3 |